immunogenicity and efficacy of two doses of the BNT vaccine administered 21 days apart in children aged 6 months to 11 years. The findings support two doses (10 μg) of BNT vaccine for children aged 5 to 11 years. In the article discussing the study, the research team of the Union Hospital Affiliated to Fujian Medical University pointed out that the risk of adverse events after the first or second dose of the vaccine is indeed higher than that of those who have not been vaccinated. However,
, Emmanuel B., et al. (2022) " Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age ". New England Journal of Medicine , 386 (1), 35-46. Shuang‑fang Fang., et al.(2022) " Correspondence: BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age ". New England Journal of Medicine . DOI: 10.1056/NEJMc2118775 What do the experts say? Qiu Nanchang, chairman targeted email list of the Taiwan Children's Infectious Diseases Association January 21, 2022 This study has met the requirements of vaccine trials, and the results can be considered to be safe and protective when administering 10μg antigenic BNT vaccine to children aged 5 to 11 years.
the trial compared the amount of antibodies produced by children aged 5 to 11 when 10μg antigen was administered to those aged 16 to 25 who received 30μg BNT new crown vaccine. The results showed no significant difference between the two, and there are data on the effectiveness of the vaccine in adults, so it is speculated that similar protective effects will be found in children. It is not known how long the effective antibody concentration in children will last; neither is the protection against the new variant virus. The efficacy and saf